This study analyzed patient data obtained from the National Health Insurance Research Database (NHIRD) in Taiwan. The NHIRD can only be accessed at the Collaboration Center of Health Information Application (CCHIA), Department of Health, Taiwan, after getting the approval from the National Health Research Institutes. Detailed information regarding the application of National Health Insurance Research Database in Taiwan: Available at: [www.mohw.gov.tw](http://www.mohw.gov.tw) Contact name: Miss Wu TEL: + 886-2-8590-6825.

Introduction {#sec005}
============

Stroke remains a leading cause of mortality worldwide \[[@pone.0151684.ref001]\]. Stroke is a complicated disease and is influenced by genetic and environmental factors and their interactions \[[@pone.0151684.ref002]\]. Accumulating evidence indicates that inflammation is important in stroke development \[[@pone.0151684.ref003]--[@pone.0151684.ref005]\].

Human cytomegalovirus (CMV) is a ubiquitous DNA virus of the *Herpesviridae* family that replicates only in humans. CMV infection is usually asymptomatic in immunocompetent patients. However, CMV infection can cause serious diseases (e.g., retinitis) in people living with HIV/AIDS (PLWHA) \[[@pone.0151684.ref006]\]. Human CMV also inhibits Akt-mediated endothelial nitric oxide synthase activation, thereby resulting in endothelial dysfunction and exerting a proatherogenic effect \[[@pone.0151684.ref007]\]. In addition, CMV infection of vascular smooth muscle cells induces production of powerful proinflammatory cytokines (e.g., leukotriene B~4~), which accelerate atherosclerosis development \[[@pone.0151684.ref008], [@pone.0151684.ref009]\].

Despite accumulating evidence suggesting that active CMV replication in vascular cells leads to atherosclerosis and stenosis \[[@pone.0151684.ref007], [@pone.0151684.ref008], [@pone.0151684.ref010]\], few studies have investigated the association between CMV infection and stroke. A prior case study reported that severe CMV infection caused central nervous system vasculitis and resulted in hemiplegia \[[@pone.0151684.ref011]\]. A recent observational study showed that CMV seropositivity was associated with increased risk of stroke \[[@pone.0151684.ref012]\], but another study found no significant association \[[@pone.0151684.ref013]\].

Stroke management and prevention should include identification and prevention of specific stroke risk factors, particularly in high-risk populations. Therefore, we conducted a nationwide population-based cohort study of the association between CMV end-organ disease and stroke among PLWHA in Taiwan during the period from 1998 through 2012.

Methods {#sec006}
=======

Background information {#sec007}
----------------------

Taiwan launched its single-payer National Health Insurance program in 1995 \[[@pone.0151684.ref014]\]. Our nationwide cohort study analyzed patient data obtained from the National Health Insurance Research Database (NHIRD), which contains health care data from more than 99% of the population in Taiwan \[[@pone.0151684.ref015]\]. The NHIRD is a large-scale computerized database derived from the system used by the Bureau of National Health Insurance (NHI) and is provided to scientists for research purposes. Patient identification codes in the NHIRD are scrambled and de-identified before being accessed by the researchers. With approval from the National Health Research Institutes, the NHIRD was accessed at the Collaboration Center of Health Information Application (CCHIA), Department of Health, Executive Yuan, Taiwan. In the NHIRD, the accuracy of diagnoses of major diseases, such as diabetes mellitus and cerebrovascular disease, has been well validated \[[@pone.0151684.ref016], [@pone.0151684.ref017]\]. This study was approved by the institutional review board of Kaohsiung Medical University.

Study subjects {#sec008}
--------------

In this cohort study, we selected adult subjects aged 15 years or older who were newly diagnosed with HIV between January 1, 1998 and December 31, 2012. A new case of HIV was defined as a patient for whom there was (1) a record of a relevant International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code (042 to 044, 7958, or V08) in an inpatient setting or three or more outpatient visits, and (2) a record of an examination for viral load (order codes: 14074B) or CD4 count (order codes: 26017A1, 14074B, 12071A, 12071B, 12073A, 12073B, 12074A, 12074B) \[[@pone.0151684.ref018]\]. Patients were excluded if they received a diagnosis of stroke (ICD-9-CM codes 430 to 437) or CMV infection (ICD-9-CM code 078.5) before an HIV diagnosis. All study subjects were followed until the study endpoints of hospitalization for stroke unclassified (ICD-9CM codes 430--437), hemorrhagic stroke (ICD-9-CM codes 430--432), or ischemic stroke (ICD-9-CM codes 433 to 437) \[[@pone.0151684.ref019]\] or until the study endpoint of death as recorded in Taiwan's national death certificate database or until December 31, 2012, the end date of the study.

Independent and potential confounding variables {#sec009}
-----------------------------------------------

The study's main explanatory variable was CMV end-organ disease after HIV diagnosis. CMV end-organ disease was defined as ICD-9-CM code 078.5 plus a prescription for an anti-CMV drug (e.g., ganciclovir or valganciclovir). Confounders controlled in the analysis included sociodemographics, comorbidities, history of opportunistic infection (OI) after HIV diagnosis, and treatment with highly active antiretroviral therapy (HAART). Sociodemographic variables included income level and urban or rural residence. Income level was calculated as the average monthly income, classified as low (≤19,200 New Taiwan Dollars \[NTD\]), intermediate (19,201 NTD to 39,999 NTD), or high (≥40,000 NTD).

The comorbidities analyzed included diabetes (ICD-9 code 250), chronic kidney disease (ICD-9 codes 580--587), hypertension (ICD-9 codes 401--405), coronary heart disease (ICD-9 codes 410--414), cancer (ICD-9 codes 140--208), and dyslipidemia (ICD-9 code 272). OIs after HIV diagnosis included *Mycobacterium tuberculosis* infection (ICD-9 codes 011--018), disseminated *Mycobacterium avium* complex infection (ICD-9 code 0312), *Pneumocystis jirovecii* pneumonia (ICD-9 code 1363), cryptococcal meningitis (ICD-9 code 3210), *Penicillium marneffei* infection (ICD-9 code 1179), toxoplasma encephalitis (ICD-9 code 130), candidiasis (ICD-9 code 112), and herpes zoster (ICD-9 code 053). Subjects were classified as having a comorbidity or OI only if the condition occurred in an inpatient setting or was recorded in three or more outpatient visits \[[@pone.0151684.ref020]\].

Statistical analysis {#sec010}
--------------------

Comparisons between groups were made using the two-sample t test, and the Pearson χ^2^ test was used to analyse categorical data. The incidence of ischemic, hemorrhagic, and all-cause stroke per 1,000 person-years and the relative hazards (RH) of stroke were calculated for HIV patients with and without CMV end-organ disease, the latter being estimated from Cox proportional-hazards models.

To identify independent risk factors for incident stroke, a time-dependent Cox proportional-hazards model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for age, sex, comorbidities, OIs, and HAART use. In these models, HAART use, CMV end-organ disease, and other OIs were regarded as time-dependent covariables \[[@pone.0151684.ref011]\], whereas other confounders including age, sex, and history of comorbidities, which were collected at baseline, were considered as fixed covariates. Adjusted HRs (AHRs) with 95% CIs were calculated to indicate the strength and direction of associations.

To examine the robustness of the main findings, we conducted sensitivity analyses after stratifying study subjects by age, sex, comorbidities, OIs, and HAART treatment. All statistical analyses were performed using the SAS 9.4 software package (SAS Institute, Cary, NC).

Results {#sec011}
=======

Patient selection {#sec012}
-----------------

We identified 23,507 individuals who were diagnosed with HIV from January 1, 1998 through December 31, 2012. After excluding those younger than 15 years (*n* = 292) and those with antecedent stroke disorder (*n* = 309), antecedent CMV infection (*n* = 16), or incomplete data (*n* = 309), 22,581 PLWHA remained for analysis ([Fig 1](#pone.0151684.g001){ref-type="fig"}). The overall mean (SD) age was 34.2 (10.8) years, and 91.1% of the subjects were male. During the follow-up period, 228 (1.01%) PLWHA had new onset of stroke, including 169 (0.75%) ischemic strokes and 59 (0.26%) hemorrhagic strokes. Among the 439 PLWHA with CMV end-organ disease, there were 17 (3.87%) all-cause strokes, including 14 (3.19%) ischemic strokes and 3 (0.68%) hemorrhagic strokes. Among the 22,142 PLWHA without CMV end-organ disease, there were 211 (0.95%) all-cause strokes, including 155 (0.70%) ischemic strokes and 56 (0.25%) hemorrhagic strokes.

![Study flow diagram.\
PLWHA, people living with HIV/AIDS; CMV, cytomegalovirus.](pone.0151684.g001){#pone.0151684.g001}

Demographic characteristics and comorbidities {#sec013}
---------------------------------------------

[Table 1](#pone.0151684.t001){ref-type="table"} shows the demographic characteristics and comorbidities of PLWHA with and without CMV end-organ disease. There was no significant difference in age, sex, or comorbidities between these groups. As compared with PLWHA without CMV end-organ disease, PLWHA with CMV end-organ disease were more likely to have other OIs during the study follow-up period. In addition, PLWHA with CMV end-organ disease were more likely to have received HAART than those without CMV end-organ disease.

10.1371/journal.pone.0151684.t001

###### Characteristics of PLWHA with and without CMV End-organ Disease.

![](pone.0151684.t001){#pone.0151684.t001g}

  Characteristic                                       No. (%) of subjects[\*](#t001fn002){ref-type="table-fn"}   P               
  ---------------------------------------------------- ---------------------------------------------------------- --------------- ---------
  Demographics                                                                                                                    
  Age, yr                                                                                                                         
      Mean ± SD                                        34.2 ± 10.6                                                34.2 ± 10.9     0.87
      15--49                                           401 (91.34)                                                20199 (91.22)   0.96
      ≥50                                              38 (8.66)                                                  1943 (8.78)     
  Sex                                                                                                                             
      Male                                             411 (93.62)                                                20164 (91.07)   0.062
      Female                                           28 (6.38)                                                  1978 (8.93)     
  Income level                                                                                                                    
      Low                                              265 (60.36)                                                13023 (58.82)   0.663
      Intermediate                                     122 (27.79)                                                6594 (29.78)    
      High                                             52 (11.85)                                                 2525 (11.40)    
  Urbanization                                                                                                                    
      Rural                                            51 (11.62)                                                 4246 (19.18)    \<0.001
      Urban                                            388 (88.38)                                                17896 (80.82)   
  Comorbidities                                                                                                                   
  Diabetes                                             7 (1.59)                                                   364 (1.64)      0.936
  CKD                                                  4 (0.91)                                                   121 (0.55)      0.308
  HTN                                                  10 (2.28)                                                  518 (2.34)      0.933
  CHD                                                  2 (0.46)                                                   155 (0.70)      0.542
  Dyslipidemia                                         4 (0.91)                                                   190 (0.86)      0.905
  Cancer                                               14 (3.19)                                                  495 (2.24)      0.183
  Opportunistic infections after HIV diagnosis                                                                                    
  TB infection                                         150 (34.17)                                                1269 (5.73)     \< .001
  Disseminated Mycobacterium avium complex infection   36 (8.20)                                                  93 (0.42)       \< .001
  Pneumocystis jirovecii pneumonia                     220 (50.11)                                                1131 (5.11)     \< .001
  Cryptococcal meningitis                              22 (5.01)                                                  160 (0.72)      \< .001
  Candidiasis                                          186 (42.37)                                                1473 (6.65)     \< .001
  Penicillium marneffei infection                      17 (3.87)                                                  134 (0.61)      \< .001
  Toxoplasma encephalitis                              10 (2.28)                                                  53 (0.24)       \< .001
  Herpes zoster                                        83 (18.91)                                                 1559 (7.04)     \< .001
  HAART                                                                                                                           
      No                                               12 (2.73)                                                  7623 (34.43)    \<0.001
      Yes                                              427 (97.27)                                                14519 (65.57)   
  Follow-up years, mean (SD)                           6.07 (3.79)                                                4.83 (3.69)     \< .001

PLWHA, people living with HIV/AIDS; SD, standard deviation; HIV, human immunodeficiency virus; CMV, cytomegalovirus; CKD, chronic kidney disease; HTN, hypertension; CHD, coronary heart disease; TB, tuberculosis; HAART, highly active antiretroviral therapy.

\*Unless otherwise stated.

Incidence rate of stroke {#sec014}
------------------------

The incidence rate of all-cause stroke per 1,000 person-years (py) was 6.38 for PLWHA with CMV end-organ disease and 1.97 for PLWHA without CMV end-organ disease (P \<0.001) ([Table 1](#pone.0151684.t001){ref-type="table"}), which was primarily attributable to a significantly higher incidence of ischemic stroke for PLWHA with CMV end-organ disease (incidence rate per 1,000 py: 5.26 vs. 1.45; P \<0.001). There was no significant difference in the incidence of hemorrhagic stroke for PLWHA with and without CMV end-organ disease (incidence rates per 1000 py: 1.13 and 0.55, respectively; p = 0.181). As compared with PLWHA without CMV end-organ disease, the RHs of incident ischemic, hemorrhagic, and all-cause stroke among PLWHA with CMV end-organ disease were 3.28 (95% CI, 1.85 to 5.80), 2.15 (95% CI, 0.67 to 6.89), and 3.00 (95% CI, 1.80 to 4.99), respectively.

The mean (SD) time to onset of incident all-cause stroke was 4.1 (3.4) and 4.6 (3.7) years from HIV diagnosis in stroke patients with and without CMV end-organ disease, respectively (P \<0.001). Among stroke patients with CMV end-organ disease, the mean (SD) time to onset of incident all-cause stroke was 1.2 (1.2) years from CMV end-organ disease. Also, among 17 stroke patients with CMV end-organ disease, 53.0% (9) occurred within one year of CMV end-organ disease; 23.5% (4) occurred between one and two years of CMV end-organ disease; and 23.5% (4) occurred after two years of CMV end-organ disease.

Association of CMV end-organ disease with incident all-cause stroke {#sec015}
-------------------------------------------------------------------

A time-dependent Cox proportional-hazards model was used to identify independent risk factors for all-cause stroke. After adjusting for age, sex, comorbidities, OIs, and HAART, CMV end-organ disease was associated with a significantly increased risk of incident all-cause stroke (AHR, 3.07; 95% CI, 1.70 to 5.55) ([Table 2](#pone.0151684.t002){ref-type="table"}). Other risk factors for incident all-cause stroke included age ≥50 years (AHR, 6.37; 95% CI, 4.76 to 8.54), hypertension (AHR, 2.11; 95% CI, 1.29 to 3.44), tuberculosis (TB) infection (AHR 1.51; 95% CI, 1.02 to 2.24), and cryptococcal meningitis (AHR, 5.24; 95% CI, 2.53 to 10.82). As compared with PLWHA with low income, those with intermediate income had a lower risk of incident all-cause stroke (AHR 0.59; 95% CI, 0.42 to 0.83). Moreover, PLWHA receiving HAART had a lower risk of incident all-cause stroke (AHR, 0.48; 95% CI, 0.35 to 0.64) than those who did not receive HAART.

10.1371/journal.pone.0151684.t002

###### Univariate and Multivariate Analyses of the Association of CMV End-organ Disease and All-cause Stroke among PLWHA.

![](pone.0151684.t002){#pone.0151684.t002g}

  Characteristic                                       Number of patients   All-cause Stroke   Univariate analysis                                           Multivariates analysis
  ---------------------------------------------------- -------------------- ------------------ ------------------------------------------------------------- -------------------------------------------------------------
  Cytomegalovirus end-organ disease                                                                                                                          
      No                                               22142                211 (0.95)         1                                                             1
      Yes                                              439                  17 (3.87)          3.00 (1.80--4.99)[\*\*\*](#t002fn003){ref-type="table-fn"}    3.07 (1.70--5.55)[\*\*\*](#t002fn003){ref-type="table-fn"}
  Demographics                                                                                                                                               
  Age, yr                                                                                                                                                    
      15--49                                           20600                134 (0.65)         1                                                             1
      ≥50                                              1981                 94 (4.75)          7.69 (5.90--10.01)[\*\*\*](#t002fn003){ref-type="table-fn"}   6.37 (4.76--8.54)[\*\*\*](#t002fn003){ref-type="table-fn"}
  Sex                                                                                                                                                        
      Male                                             20575                189 (0.94)         1                                                             1
      Female                                           2006                 37 (1.88)          1.63 (1.15--2.32)[\*\*](#t002fn002){ref-type="table-fn"}      0.95 (0.65--1.38)
  Income level                                                                                                                                               
      Low                                              13288                163 (1.23)         1                                                             1
      Intermediate                                     6716                 41 (0.61)          0.55 (0.39--0.77)[\*\*\*](#t002fn003){ref-type="table-fn"}    0.59 (0.42--0.83)[\*\*](#t002fn002){ref-type="table-fn"}
      High                                             2577                 24 (0.93)          0.73 (0.48--1.12)                                             0.77 (0.50--1.18)
  Urbanization                                                                                                                                               
      Rural                                            4297                 52 (1.21)          1                                                             1
      Urban                                            18284                176 (0.99)         0.66 (0.49--0.91)[\*\*](#t002fn002){ref-type="table-fn"}      0.84 (0.61--1.17)
  Comorbidity                                                                                                                                                
  Diabetes                                                                                                                                                   
      No                                               22210                216 (0.99)         1                                                             1
      Yes                                              371                  12 (3.23)          4.44 (2.48--7.95)[\*\*\*](#t002fn003){ref-type="table-fn"}    1.16 (0.60--2.24)
  CKD                                                                                                                                                        
      No                                               22456                225 (1.00)         1                                                             1
      Yes                                              125                  3 (2.40)           3.27 (1.05--10.22)[\*](#t002fn001){ref-type="table-fn"}       1.18 (0.37--3.82)
  HTN                                                                                                                                                        
      No                                               22053                202 (0.92)         1                                                             1
      Yes                                              528                  26 (4.92)          6.99 (4.64--10.53)[\*\*\*](#t002fn003){ref-type="table-fn"}   2.11 (1.29--3.44)\*\*
  CHD                                                                                                                                                        
      No                                               22424                224 (1.00)         1                                                             1
      Yes                                              157                  4 (2.55)           2.89 (1.07--7.76)[\*](#t002fn001){ref-type="table-fn"}        0.43 (0.15--1.22)
  Dyslipidemia                                                                                                                                               
      No                                               22387                221 (0.99)         1                                                             1
      Yes                                              194                  7 (3.61)           4.79 (2.26--10.16)[\*\*\*](#t002fn003){ref-type="table-fn"}   1.31 (0.57--3.02)
  Cancer                                                                                                                                                     
      No                                               22072                218 (0.99)         1                                                             1
      Yes                                              509                  10 (1.96)          2.58 (1.37--4.86)[\*\*](#t002fn002){ref-type="table-fn"}      1.31 (0.68--2.52)
  Opportunistic infections after HIV diagnosis                                                                                                               
  TB infection                                                                                                                                               
      No                                               21162                184 (0.87)         1                                                             1
      Yes                                              1419                 44 (3.10)          1.75 (1.21--2.51)\*\*                                         1.51 (1.02--2.24)[\*](#t002fn001){ref-type="table-fn"}
  Disseminated Mycobacterium avium complex infection                                                                                                         
      No                                               22452                224 (1.00)         1                                                             1
      Yes                                              129                  4 (3.10)           2.84 (1.06--7.62)[\*](#t002fn001){ref-type="table-fn"}        1.94 (0.68--5.53)
  Pneumocystis jirovecii pneumonia                                                                                                                           
      No                                               21230                209 (0.98)         1                                                             1
      Yes                                              1351                 19 (1.41)          1.19 (0.74--1.90)                                             1.03 (0.60--1.77)
  Cryptococcal meningitis                                                                                                                                    
      No                                               22399                220 (0.98)         1                                                             1
      Yes                                              182                  8 (4.40)           4.26 (2.10--8.62)[\*\*\*](#t002fn003){ref-type="table-fn"}    5.24 (2.53--10.82)[\*\*\*](#t002fn003){ref-type="table-fn"}
  Candidiasis                                                                                                                                                
      No                                               20922                203 (0.97)         1                                                             1
      Yes                                              1659                 25 (1.51)          1.14 (0.75--1.72)                                             0.98 (0.61--1.56)
  Penicillium marneffei infection                                                                                                                            
      No                                               22430                223 (0.99)         1                                                             1
      Yes                                              151                  5 (3.31)           2.22 (0.91--5.38)                                             1.75 (0.70--4.36)
  Toxoplasma encephalitis                                                                                                                                    
      No                                               22518                226 (1.00)         1                                                             1
      Yes                                              63                   2 (3.17)           2.73 (0.68--10.98)                                            2.25 (0.55--9.25)
  Herpes zoster                                                                                                                                              
      No                                               20939                207 (0.99)         1                                                             1
      Yes                                              1642                 21 (1.28)          0.87 (0.55--1.36)                                             0.78 (0.49--1.23)
  HAART                                                                                                                                                      
      No                                               7635                 81 (1.06)          1                                                             1
      Yes                                              14946                147 (0.98)         0.44 (0.34--0.58)[\*\*\*](#t002fn003){ref-type="table-fn"}    0.48 (0.35--0.64)[\*\*\*](#t002fn003){ref-type="table-fn"}

\* \< .05

\*\* \< .01

\*\*\* \< .001

PLWHA, people living with HIV/AIDS; AHR, adjusted hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; CMV, cytomegalovirus; CKD, chronic kidney disease; HTN, hypertension; CHD, coronary heart disease; TB, tuberculosis; HAART, highly active antiretroviral therapy.

Association of CMV end-organ disease with incident ischemic and hemorrhagic stroke {#sec016}
----------------------------------------------------------------------------------

[Table 3](#pone.0151684.t003){ref-type="table"} shows the time-dependent multinomial Cox regression for factors associated with ischemic and hemorrhagic stroke among PLWHA. CMV end-organ disease significantly increased the risk of incident ischemic stroke (AHR, 3.14; 95% CI, 1.49 to 6.62) but not incident hemorrhagic stroke (AHR, 2.52; 95% CI, 0.64 to 9.91).

10.1371/journal.pone.0151684.t003

###### Time-dependent Multinomial Regression Analysis of the Association of CMV End-organ Disease with Ischemic and Hemorrhagic Stroke among PLWHA.

![](pone.0151684.t003){#pone.0151684.t003g}

  Variables                                            Ischemic stroke                                               Hemorrhagic stroke
  ---------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------
  Cytomegalovirus end-organ disease                    3.14 (1.49--6.62)[\*\*](#t003fn002){ref-type="table-fn"}      2.52 (0.64--9.91)
  Demographics                                                                                                       
  Age, yr                                                                                                            
      15--49                                           1                                                             1
      ≥50                                              7.22 (5.14--10.13)[\*\*\*](#t003fn003){ref-type="table-fn"}   4.10 (2.02--8.32)[\*\*\*](#t003fn003){ref-type="table-fn"}
  Sex                                                                                                                
      Male                                             1                                                             1
      Female                                           1.18 (0.78--1.79)                                             0.46 (0.17--1.24)
  Income level                                                                                                       
      Low                                              1                                                             1
      Intermediate                                     1.04 (0.65--1.67)                                             3.00 (0.90--9.97)
      High                                             0.70 (0.40--1.21)                                             1.20 (0.32--4.55)
  Urbanization                                                                                                       
      Rural                                            1                                                             1
      Urban                                            0.86 (0.59--1.26)                                             0.79 (0.45--1.40)
  Comorbidity                                                                                                        
  Diabetes                                             1.61 (0.73--3.58)                                             0.35 (0.04--3.26)
  CKD                                                  \-                                                            5.77 (1.28--26.09)[\*](#t003fn001){ref-type="table-fn"}
  HTN                                                  1.57 (0.81--3.02)                                             3.86 (1.44--10.40)[\*\*](#t003fn002){ref-type="table-fn"}
  CHD                                                  0.58 (0.19--1.83)                                             \-
  Dyslipidemia                                         1.43 (0.52--3.95)                                             0.75 (0.10--5.97)
  Cancer                                               1.04 (0.43--2.52)                                             2.05 (0.60--7.04)
  Opportunistic infections after HIV diagnosis                                                                       
  TB infection                                         1.56 (0.98--2.49)                                             1.36 (0.60--3.11)
  Disseminated Mycobacterium avium complex infection   2.49 (0.78--7.96)                                             \-
  Pneumocystis jirovecii pneumonia                     1.16 (0.60--2.22)                                             0.69 (0.18--2.66)
  Cryptococcal meningitis                              5.86 (2.67--12.85)[\*\*\*](#t003fn003){ref-type="table-fn"}   2.71 (0.41--18.00)
  Candidiasis                                          0.94 (0.52--1.72)                                             1.19 (0.45--3.16)
  Penicillium marneffei infection                      1.27 (0.38--4.30)                                             3.31 (0.68--16.05)
  Toxoplasma encephalitis                              2.90 (0.61--13.68)                                            \-
  Herpes zoster                                        0.73 (0.42--1.27)                                             1.01 (0.44--2.33)
  HAART                                                                                                              
      No                                               1                                                             1
      Yes                                              0.52 (0.37--0.74)[\*\*\*](#t003fn003){ref-type="table-fn"}    0.41 (0.23--0.72)[\*\*](#t003fn002){ref-type="table-fn"}

\* \< .05

\*\* \< .01

\*\*\* \< .001

PLWHA, people living with HIV/AIDS; AHR, adjusted hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; CMV, cytomegalovirus; CKD, chronic kidney disease; HTN, hypertension; CHD, coronary heart disease; TB, tuberculosis; HAART, highly active antiretroviral therapy.

Sensitivity analysis of the association between CMV end-organ disease and stroke {#sec017}
--------------------------------------------------------------------------------

[Fig 2](#pone.0151684.g002){ref-type="fig"} shows the results of sensitivity analysis of the association between CMV end-organ disease and stroke after adjusting for patient demographics, comorbidities, OIs, and HAART. CMV end-organ disease was significantly associated with higher risk of all-cause stroke in all PLWHA subgroups except female patients, those not receiving HAART, those with intermediate or high income, and those with TB infection, *P*. *jirovecii* pneumonia, or candidiasis. In addition, CMV end-organ disease significantly increased the risk of ischemic stroke in all PLWHA subgroups except patients aged 15 to 49 years, those with intermediate or high income, and those with TB infection, *P*. *jirovecii* pneumonia, or candidiasis. CMV end-organ disease was not associated with a higher risk of hemorrhagic stroke in any PLWHA subgroup.

![Sensitivity analysis of the association between CMV end-organ disease and stroke in PLWHA subgroups, after adjustment for patient demographics, comorbidities, and antiretroviral treatment.\
**Values greater than 1.0 indicate increased risk.** AHR, adjusted hazard ratio; CMV, cytomegalovirus; PLWHA, people living with HIV/AIDS; HAART, highly active antiretroviral therapy; CHD, coronary heart disease; MAC, Mycobacterium avium complex; PJP, Pneumocystis jirovecii pneumonia; PM, Penicillium marneffei.](pone.0151684.g002){#pone.0151684.g002}

Discussion {#sec018}
==========

In this large cohort study of 22,581 Taiwanese PLWHA, the overall incidence rate of all-cause stroke was 2.08 per 1,000 py. Controlling for potential confounders, the risk of incident all-cause stroke was higher among PLWHA with CMV end-organ disease than among those without CMV end-organ disease. When type of stroke was considered, CMV end-organ disease significantly increased the risk of ischemic stroke but not hemorrhagic stroke.

This study found that the incidence rates of all-cause, ischemic, and hemorrhagic strokes were 2.08, 1.54, and 0.54 per 1,000 py among PLWHA, respectively. In a comparison with other countries, the rate of incident all-cause stroke among PLWHA in Taiwan was lower than that in Danish HIV cohort (2.68 per 1000 PY) \[[@pone.0151684.ref021]\]. Also, the rate of incident ischemic stroke among PLWHA in Taiwan was similar to that in Swiss HIV cohort (1.73 per 1000 PY) \[[@pone.0151684.ref022]\], but lower than that among PLWHA in U.S. (5.27 per 1000 PY) \[[@pone.0151684.ref022]\].An association between CMV disease and vasculopathy was reported in previous studies \[[@pone.0151684.ref023]\]. However, findings from studies of the link between CMV disease and incident stroke are limited and inconsistent \[[@pone.0151684.ref011]--[@pone.0151684.ref013]\]. A case study reported that CMV end-organ disease in an HIV-infected patient induced central nervous system vasculitis, which resulted in multiple small-vessel cerebral infarctions \[[@pone.0151684.ref011]\]. The magnetic resonance imaging findings showed interval evolution of infarctions while the patient received valganciclovir treatment \[[@pone.0151684.ref011]\]. A recent observational study found that the proportion of patients with CMV seropositivity was significantly higher among stroke patients than among matched non-stroke patients \[[@pone.0151684.ref012]\]. However, a recent Italian Cohort Naive Antiretrovirals (ICONA) study showed that HIV patients who were CMV-seropositive at baseline did not have a significantly higher risk of cerebrovascular diseases than those who were CMV-seronegative \[[@pone.0151684.ref013]\]. Although the ICONA study was the first cohort study to evaluate the link between CMV infection and stroke, the association of CMV infection and stroke might have been underestimated in that study because many of the CMV-seropositive patients could have had asymptomatic CMV infection \[[@pone.0151684.ref013]\]. A prior study showed that asymptomatic CMV infection was not associated with atherosclerosis development \[[@pone.0151684.ref024]\]. The present study followed 22,050 HIV patients and evaluated the association of CMV end-organ disease with stroke. Time-dependent Cox regression showed that CMV end-organ disease significantly increased the risk of all-cause stroke. When type of stroke was considered, CMV end-organ disease significantly increased the risk of ischemic stroke but not hemorrhagic stroke. These findings suggest that CMV end-organ disease was an independent predictor of ischemic stroke among PLWHA.

CMV-induced inflammation, vasculopathy, and atherosclerosis may have increased the risk of incident stroke among PLWHA with CMV end-organ disease in this study. CMV end-organ disease of smooth muscle cells can cause vascular cell inflammation and proliferation through generation of reactive oxygen species and activation of nuclear factor kB \[[@pone.0151684.ref009], [@pone.0151684.ref025]\]. CMV end-organ disease of smooth muscle cells can also initiate proinflammatory gene transcription (e.g., 5-lipoxygenase expression), while 5-lipoxgenase induces synthesis of leukotriene B~4~, a powerful proinflammatory cytokine, and may contribute to atherosclerosis and stenosis \[[@pone.0151684.ref008]\]. Also, CMV end-organ disease of vascular cells caused the stimulation of fractalkine-CX3CR1 interaction, which resulted in the endothelial damage \[[@pone.0151684.ref026]\]. In addition, human CMV inhibits Akt-mediated endothelial nitric oxide synthase activation, which leads to endothelial dysfunction and exerts a proatherogenic effect \[[@pone.0151684.ref007]\]. Taken together, these mechanisms indicate that active CMV replication in vascular endothelial cells may create an atherosclerotic environment that results in restriction of blood flow and promotion of ischemic stroke.

This study is the largest cohort study of the association between CMV end-organ disease and subsequent stroke development. Our research design, which included unbiased subject selection and strict criteria for CMV diagnosis, increased the validity of the findings. In addition, this nationwide population-based study traced all PLWHA, and referral bias was minimized because all medical care was covered by the Taiwan National Health Insurance. Moreover, the large sample size was powered to detect even very small differences between PLWHA with and without CMV end-organ disease. Additionally, the timing of CMV end-organ disease was ascertained in all patients, and CMV end-organ disease was regarded as a time-dependent variable in the analysis. Longitudinal studies that do not account for changes in exposure during the study period do not yield precise estimates of the effect of the exposure on outcomes \[[@pone.0151684.ref027]\].

The present study has some limitations. First, some potential risk factors, including smoking and obesity, could not be ascertained. However, some smoking-related comorbidities (e.g., hypertension and coronary heart disease) were included in the analysis. Second, diagnoses of CMV end-organ disease and stroke that rely on administrative claims data recorded by physicians or hospitals may be less accurate than diagnoses made in a prospective clinical setting, but there is no reason to suspect that the validity of claims data would differ with a patient's CMV status. CMV end-organ disease in this study was defined strictly according to the relevant ICD-9 codes and was confirmed by records of treatment with anti-CMV drugs, thereby maximizing diagnostic validity. Furthermore, a stroke event was defined as a patient hospitalized for stroke. A previous study confirmed that the accuracy of the Taiwan NHIRD in recording stroke diagnoses was high (98%) \[[@pone.0151684.ref016]\]. Third, CD4 counts and viral loads---the index of advanced-stage of HIV infection---were unavailable in our database. However, our study used the opportunistic infections as the proxy for advanced-stage of HIV infection. All opportunistic infections among PLWHA were included in the multivariate analysis. Finally, this study was limited to the evaluation of the association between CMV end-organ disease and incident stroke among PLWHA. Although this study revealed an association between CMV end-organ disease and stroke, the generalizability of our findings to other non-HIV subgroups requires confirmation.

Conclusion {#sec019}
==========

This nationwide, long-term cohort study revealed a link between CMV end-organ disease and stroke among PLWHA. CMV end-organ disease was associated with a higher risk of incident all-cause stroke. When type of stroke was considered, CMV iend-organ disease was significantly associated with an increased risk of ischemic stroke but not hemorrhagic stroke. These findings suggest that CMV end-organ disease was an independent predictor of ischemic stroke among PLWHA.
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